XML 260 R127.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, divestment of product rights and out-licensing - Purchase price allocation for business combinations (Details) - USD ($)
$ in Millions
13 Months Ended
Dec. 31, 2023
Dec. 31, 2024
Sep. 30, 2024
Jul. 01, 2024
Sep. 30, 2023
Dec. 31, 2022
Nov. 21, 2022
Disclosure of detailed information about business combination [line items]              
Goodwill $ 8,926.0 $ 8,946.0       $ 8,926.0  
BELKIN Vision Ltd.              
Disclosure of detailed information about business combination [line items]              
Property, plant and equipment     $ 1.0        
Deferred tax assets     6.0        
Inventories     3.0        
Cash and cash equivalents     3.0        
Other current assets     2.0        
Deferred tax liabilities     (17.0)        
Provisions and other current liabilities     (1.0)        
Net identifiable assets acquired     72.0        
Goodwill     20.0 $ 20.0      
Consideration transferred     92.0 92.0      
Acquired liquidity     (3.0)        
Net assets recognized as a result of business combinations     89.0        
Purchase consideration              
Cash paid at closing     64.0        
Cash expected to be paid after closing     2.0        
Previously-held FVOCI financial investments     20.0 $ 20.0      
Contingent consideration     6.0        
BELKIN Vision Ltd. | Currently marketed products              
Disclosure of detailed information about business combination [line items]              
Intangible assets     $ 75.0        
Aerie Pharmaceuticals, Inc.              
Disclosure of detailed information about business combination [line items]              
Property, plant and equipment 27.0           $ 27.0
Right-of-use assets 29.0           29.0
Deferred tax assets 189.0           189.0
Inventories 49.0           49.0
Trade receivables 70.0           70.0
Short-term investments 79.0           79.0
Cash and cash equivalents 78.0           78.0
Other assets 15.0           15.0
Lease liabilities (27.0)           (27.0)
Deferred tax liabilities (255.0)           (255.0)
Provisions and other non-current and current liabilities (235.0)           (235.0)
Current income tax liabilities (2.0)           (46.0)
Trade payables (3.0)           (3.0)
Financial debts (316.0)           (316.2)
Net identifiable assets acquired 723.0           679.0
Goodwill 21.0       $ 21.0   65.0
Consideration transferred 744.0           744.0
Acquired liquidity (78.0)           (78.0)
Net assets recognized as a result of business combinations 666.0           666.0
Measurement period adjustments              
Current income tax liabilities 44.0            
Net identifiable assets acquired 44.0            
Goodwill (44.0)            
Total purchase consideration 0.0            
Aerie Pharmaceuticals, Inc. | Currently marketed products              
Disclosure of detailed information about business combination [line items]              
Intangible assets 850.0           850.0
Aerie Pharmaceuticals, Inc. | Acquired in-process research & development              
Disclosure of detailed information about business combination [line items]              
Intangible assets $ 175.0           $ 175.0